INFO & CONTACTS:  +39 02 2390 1
Verzoni Elena

Dott.ssa Verzoni Elena

Medico

Contacts
  • Mail: elena.verzoni@istitutotumori.mi.it
Specialty / Department
  • Oncologia Medica

Elena Verzoni, laureata in Medicina e Chirurgia c/o l'Università degli Studi di Milano dove ha successivamente conseguito la Specialità in Oncologia Medica nel 2007. Da allora membro dello Staff di Oncologia Medica (oggi SSD Oncologia Medica Genitourinaria e Programma Prostata), con da sempre una passione per l'Oncologia Genitourinaria, con focus sui tumori del rene e della prostata. PI di studi clinici multicentrici nazionali e internazionali di fase I, II, III e appassionata di ricerca traslazionale. È consulente scientifico per aziende farmaceutiche, membro di comitati scientifici e di associazioni come ASCO, ESMO, AIOM e Meet-URO. Membro del panel delle linee guida nazionali AIOM sul tumore del rene e della prostata. Autrice/coautrice di oltre 150 pubblicazioni e professore abilitato di II fascia.

Membro attivo del team multidisciplinare delle patologie Genitourinarie ed estensore PDTA patologia renale e prostatica per INT.

Per prenotare una visita può utilizzare il servizio online (clicca qui), contatta​re il CUP  +39 0223901 oppure recarsi direttamente agli sportelli della Fondazione.

Genitourinary Medical Oncology

A double-blind randomised phase III trial evaluating the efficacy of ADT +/- darolutamide in de novo metastatic prostate cancer patients with vulnerable functional ability and not elected for docetaxel or androgen recept

A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Study of Investigational Agents With or Without Pembrolizumab in Participants with PD-1/L1 Refractory Locally Advanced or Metastatic Urothelial Carcinoma (KEYMAKER-U04

A Phase 1/2 Randomized, Umbrella Study to Evaluate the Efficacy and Safety of MK-2870 Plus Enfortumab Vedotin (EV) in Combination With Pembrolizumab, as Treatment for Participants With Advanced Urothelial Carcinoma (KEYM

A Phase 1/2, Open-label Umbrella Substudy of MK-2400-U01 Master Protocol to Evaluate the Safety and Efficacy of Ifinatamab Deruxtecan-based Treatment Combinations or Ifinatamab Deruxtecan Alone in Participants With Metas

A Phase 3, Open-label, Multicenter, Randomized Study of Xaluritamig Plus Abiraterone Versus Investigator’s Choice in Participants with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer

A phase Ib/II open-label, multi-center study of the DNA protein kinase inhibitor AMO959 with lutetium (177Lu) vipivotide tetraxetan (AAA617) in combination with an androgen receptor pathway inhibitor (ARPI) in adult part

A Randomised, Double-blind, Placebo-controlled, Phase III Study of Adjuvant Saruparib (AZD5305) in Patients with BRCAm Localised High-Risk Prostate Cancer Receiving Radiotherapy with Androgen Deprivation Therapy (EvoPAR-

A Randomized, Double-Blind, Active-Control, Multicenter Phase 3 Trial of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma

A two part, Phase 1 dose escalation and expansion followed by randomized Phase 2, multicenter, study to assess the safety and efficacy of the combination of tulmimetostat (DZR123) and JSB462 (ARV-766) vs standard of care

Last update: 04/06/2026

Subscribe to the newsletter

Sign up for our newsletter to stay informed about news, events, and updates from the Institute

Subscribe